Koninklijke Philips (PHG) AI Stock Analysis

Company Guidance

Philips reiterated its full year comparable sales growth outlook of 3% to 4.5%, with Diagnosis & Treatment expected to deliver comparable sales growth at the upper end of the low single-digit range, Connected Care within the 3% to 4.5% range and Personal Health at the lower end of the high single-digit growth rate; adjusted EBITA margin remains 13.5% to 14%, including a U.S. tariff refund benefit of approximately 1%, and free cash flow remains EUR 1.5 billion to EUR 1.7 billion, including a net U.S. tariff refund benefit of approximately EUR 200 million. The outlook includes currently known tariffs and assumes payment of the U.S. DOJ settlement in the first quarter of 2027, subject to finalization of the relevant documentation, and excludes other ongoing Philips Respironics related proceedings, including the investigation by the U.S. State Attorneys General. Philips continues to expect China sales to be broadly stable for the full year, with growth in Personal Health offsetting a decline in health system businesses, and expects full year input cost pressures at the high double-digit million euros at group level. The company also reiterated its mid-single-digit comparable sales growth CAGR over '26 to '28 and a mid-teen adjusted EBITA margin by 2028, with a EUR 1.5 billion productivity savings target by the end of 2028.